Project Grant R03CA307796
Award Date 8/14/26
Completion Date 7/31/27
Dollars Obligated $163K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Boston, MA 02114, USA
Similar Awards
- The National Cancer Institute awarded The General Hospital Corporation, doing business as Massachusetts General Hospital, $161,460 under the Cancer Research Manpower program (CFDA 93.398) on June 1, 2026, to develop quantitative predictive dosimetry for transarterial radioembolization (TARE) in hepatocellular carcinoma treatment. The funded research will design a novel quantitative TARE dosimetry framework capable of predicting realistic yttrium-90 dose distributions to tumor tissue while...
- The National Institutes of Health National Cancer Institute awarded $421,825 to The General Hospital Corporation (Massachusetts General Hospital) on September 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop an improved fibrin-targeted radiopharmaceutical for gastric cancer treatment. The project addresses advanced gastric cancer, for which chemotherapy remains the standard treatment but nearly all patients eventually relapse or experience disease progression. The...
- The National Cancer Institute, part of the Department of Health and Human Services, awarded $424,256 to The General Hospital Corporation (Massachusetts General Hospital, Research Management Division) on September 1, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop a computational framework for optimal immune monitoring during cancer treatment. The project constructs compartmental models connecting tissue-level lymphocyte dynamics to blood count data,...
- The National Cancer Institute awarded The General Hospital Corporation (Massachusetts General Hospital) $659,201 on June 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to conduct research on the integrated stress response in glioblastoma pathogenesis and response to therapy. The funded research investigates how glioma stem cells survive and proliferate within the hostile glioblastoma microenvironment through adaptive stress response mechanisms. The work focuses on the...
- The National Institutes of Health National Cancer Institute awarded Massachusetts General Hospital (The General Hospital Corporation) $707,798 on April 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to determine mechanisms of heterogeneous treatment response in glioblastoma using multi-omic and multi-organ approaches. The research identifies transcriptional, genetic, neuronal, and immunological factors influencing glioblastoma formation, progression, and treatment response,...
- The Massachusetts General Hospital will receive $826,584 under a three-year Project Grant award from the Department of the Army Medical Command's Military Medical Research and Development program. The grant will fund research into the mechanisms mediating the immune response after proton versus photon radiotherapy in IDH-mutant liver cancer. The study aims to investigate medical solutions for the battlefield and transform health care for service members and the public through innovative...
- The National Cancer Institute awarded The General Hospital Corporation (Massachusetts General Hospital) $682,140 for Project Grant R01CA315856 on June 4, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394). The award funds development of SPIDER (Synthetic Potentiated Immunogenic Depot Engaged by Radiation), a localized drug delivery platform designed to improve treatment outcomes for locally advanced non-small cell lung cancer. SPIDER uses radiation-responsive...
- Federal Project Grant Award Summary The National Cancer Institute awarded Massachusetts General Hospital a $416,818 Project Grant under the Cancer Treatment Research program (CFDA 93.395) for the period August 1, 2025 through July 31, 2027. The award supports preclinical research investigating whether physical activity enhances Chimeric Antigen Receptor (CAR)-T cell immunotherapy effectiveness in metastatic breast cancer by normalizing the tumor microenvironment. The research will employ...
- The National Cancer Institute awarded The General Hospital Corporation (doing business as Massachusetts General Hospital) $682,561 on September 1, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop a non-invasive molecular magnetic resonance imaging biomarker for early detection of pancreatic ductal adenocarcinoma. The research will develop secretagogue-stimulated zinc-secretion MRI (SSZS-MRI), which measures transient hormone-evoked extracellular zinc...
- The federal Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides $1,480,488 to Brigham & Women's Hospital Inc. to research the combination of mRNA nanotherapy with standard antiangiogenic/immunotherapy for hepatocellular carcinoma (HCC). The research project runs from September 1, 2023 to August 31, 2026. As part of this effort, Massachusetts General Hospital will conduct preclinical studies to evaluate the...